CORCEPT THERAPEUTICS INC Revenue
CORCEPT THERAPEUTICS INC (CORT) reported Revenue of $256.15 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-07-29
- CORCEPT THERAPEUTICS INC revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $256.15M, a 31.74% increase year-over-year.
- CORCEPT THERAPEUTICS INC revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $164.90M, a 4.89% increase year-over-year.
- CORCEPT THERAPEUTICS INC revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $202.13M, a 11.12% increase year-over-year.
- CORCEPT THERAPEUTICS INC revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $207.64M, a 13.75% increase year-over-year.
- CORCEPT THERAPEUTICS INC revenue from contract with customer, excluding assessed tax for fiscal 2025 was $761.41M, a 12.79% increase from fiscal 2024.
- CORCEPT THERAPEUTICS INC revenue from contract with customer, excluding assessed tax for fiscal 2024 was $675.04M, a 39.94% increase from fiscal 2023.
- CORCEPT THERAPEUTICS INC revenue from contract with customer, excluding assessed tax for fiscal 2023 was $482.38M, a 20.04% increase from fiscal 2022.
- CORCEPT THERAPEUTICS INC revenue from contract with customer, excluding assessed tax for fiscal 2022 was $401.86M, a 9.80% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $256.15M 10-Q · filed 2026-07-29 | $421.05M 10-Q · filed 2026-07-29 | $623.17M derived: sum of 3 quarters · filed 2026-07-29 | $830.81M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $164.90M 10-Q · filed 2026-04-30 | $367.03M derived: sum of 2 quarters · filed 2026-04-30 | $574.67M derived: sum of 3 quarters · filed 2026-04-30 | $769.10M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $202.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $409.76M derived: sum of 2 quarters · filed 2026-02-24 | $604.19M derived: sum of 3 quarters · filed 2026-07-29 | $761.41M 10-K · filed 2026-02-24 |
| 2025-09-30 | $207.64M 10-Q · filed 2025-11-04 | $402.07M derived: sum of 2 quarters · filed 2026-07-29 | $559.28M 10-Q · filed 2025-11-04 | $741.17M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $194.43M 10-Q · filed 2026-07-29 | $351.64M 10-Q · filed 2026-07-29 | $533.53M derived: sum of 3 quarters · filed 2026-07-29 | $716.08M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $157.21M 10-Q · filed 2026-04-30 | $339.10M derived: sum of 2 quarters · filed 2026-04-30 | $521.65M derived: sum of 3 quarters · filed 2026-04-30 | $685.45M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $181.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $364.44M derived: sum of 2 quarters · filed 2026-02-24 | $528.23M derived: sum of 3 quarters · filed 2026-02-24 | $675.04M 10-K · filed 2026-02-24 |
| 2024-09-30 | $182.55M 10-Q · filed 2025-11-04 | $346.34M derived: sum of 2 quarters · filed 2025-11-04 | $493.15M 10-Q · filed 2025-11-04 | $628.55M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $163.80M 10-Q · filed 2025-07-31 | $310.60M 10-Q · filed 2025-07-31 | $446.01M derived: sum of 3 quarters · filed 2026-02-24 | $569.61M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $146.81M 10-Q · filed 2025-05-05 | $282.21M derived: sum of 2 quarters · filed 2026-02-24 | $405.81M derived: sum of 3 quarters · filed 2026-02-24 | $523.53M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $135.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $259.01M derived: sum of 2 quarters · filed 2026-02-24 | $376.72M derived: sum of 3 quarters · filed 2026-02-24 | $482.38M 10-K · filed 2026-02-24 |
| 2023-09-30 | $123.60M 10-Q · filed 2024-10-30 | $241.32M derived: sum of 2 quarters · filed 2024-10-30 | $346.97M 10-Q · filed 2024-10-30 | $450.03M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $117.72M 10-Q · filed 2024-07-29 | $223.37M 10-Q · filed 2024-07-29 | $326.43M derived: sum of 3 quarters · filed 2025-02-26 | $428.15M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $105.65M 10-Q · filed 2024-05-01 | $208.71M derived: sum of 2 quarters · filed 2025-02-26 | $310.44M derived: sum of 3 quarters · filed 2025-02-26 | $413.82M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $103.06M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $204.78M derived: sum of 2 quarters · filed 2025-02-26 | $308.17M derived: sum of 3 quarters · filed 2025-02-26 | $401.86M 10-K · filed 2025-02-26 |
| 2022-09-30 | $101.73M 10-Q · filed 2023-11-01 | $205.11M derived: sum of 2 quarters · filed 2023-11-01 | $298.80M 10-Q · filed 2023-11-01 | $397.62M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $103.39M 10-Q · filed 2023-08-02 | $197.07M 10-Q · filed 2023-08-02 | $295.90M derived: sum of 3 quarters · filed 2024-02-15 | $392.03M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $93.69M 10-Q · filed 2023-05-03 | $192.51M derived: sum of 2 quarters · filed 2024-02-15 | $288.64M derived: sum of 3 quarters · filed 2024-02-15 | $380.23M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $98.82M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $194.95M derived: sum of 2 quarters · filed 2024-02-15 | $286.54M derived: sum of 3 quarters · filed 2024-02-15 | $365.98M 10-K · filed 2024-02-15 |
| 2021-09-30 | $96.13M 10-Q · filed 2022-11-03 | $187.72M derived: sum of 2 quarters · filed 2022-11-03 | $267.16M 10-Q · filed 2022-11-03 | $352.89M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $91.59M 10-Q · filed 2022-08-04 | $171.03M 10-Q · filed 2022-08-04 | $256.76M derived: sum of 3 quarters · filed 2022-08-04 | $343.09M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $79.44M 10-Q · filed 2022-05-05 | $165.17M derived: sum of 2 quarters · filed 2022-05-05 | $251.50M derived: sum of 3 quarters · filed 2022-05-05 | $340.06M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $85.73M 10-K · filed 2021-02-23 | $172.06M derived: sum of 2 quarters · filed 2021-11-03 | $260.63M derived: sum of 3 quarters · filed 2021-11-03 | $353.87M 10-K · filed 2023-02-28 |
| 2020-09-30 | $86.33M 10-Q · filed 2021-11-03 | $174.89M derived: sum of 2 quarters · filed 2021-11-03 | $268.14M 10-Q · filed 2021-11-03 | $356.03M derived: sum of 4 quarters · filed 2021-11-03 |
| 2020-06-30 | $88.56M 10-Q · filed 2021-07-29 | $181.81M 10-Q · filed 2021-07-29 | $269.71M derived: sum of 3 quarters · filed 2021-07-29 | $351.21M derived: sum of 4 quarters · filed 2021-07-29 |
| 2020-03-31 | $93.25M 10-Q · filed 2021-05-06 | $181.14M derived: sum of 2 quarters · filed 2021-05-06 | $262.65M derived: sum of 3 quarters · filed 2021-05-06 | $334.90M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $87.89M 10-K · filed 2021-02-23 | $169.40M derived: sum of 2 quarters · filed 2021-02-23 | $241.66M derived: sum of 3 quarters · filed 2021-02-23 | $306.49M 10-K · filed 2022-02-15 |
| 2019-09-30 | $81.50M 10-K · filed 2021-02-23 | $153.76M derived: sum of 2 quarters · filed 2021-02-23 | $218.59M 10-Q · filed 2020-11-03 | $285.42M derived: sum of 4 quarters · filed 2021-02-23 |
| 2019-06-30 | $72.26M 10-K · filed 2021-02-23 | $137.09M 10-Q · filed 2020-08-04 | $203.92M derived: sum of 3 quarters · filed 2021-02-23 | $268.36M derived: sum of 4 quarters · filed 2021-02-23 |
| 2019-03-31 | $64.83M 10-K · filed 2021-02-23 | $131.66M derived: sum of 2 quarters · filed 2021-02-23 | $196.10M derived: sum of 3 quarters · filed 2021-02-23 | $258.42M derived: sum of 4 quarters · filed 2021-02-23 |
| 2018-12-31 | $66.83M 10-K · filed 2020-02-24 | $131.28M derived: sum of 2 quarters · filed 2020-02-24 | $193.59M derived: sum of 3 quarters · filed 2020-02-24 | $251.25M 10-K · filed 2021-02-23 |
| 2018-09-30 | $64.44M 10-K · filed 2020-02-24 | $126.76M derived: sum of 2 quarters · filed 2020-02-24 | $184.42M 10-Q · filed 2019-11-07 | $237.70M derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-06-30 | $62.31M 10-K · filed 2020-02-24 | $119.97M 10-Q · filed 2019-08-01 | $173.25M derived: sum of 3 quarters · filed 2020-02-24 | $216.01M derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-03-31 | $57.66M 10-K · filed 2020-02-24 | $110.94M derived: sum of 2 quarters · filed 2020-02-24 | $153.70M derived: sum of 3 quarters · filed 2020-02-24 | $189.26M derived: sum of 4 quarters · filed 2020-02-24 |
| 2017-12-31 | $53.28M 10-K · filed 2019-02-26 | $96.04M derived: sum of 2 quarters · filed 2019-02-26 | $131.60M derived: sum of 3 quarters · filed 2019-02-26 | $159.20M 10-K · filed 2020-02-24 |
| 2017-09-30 | $42.76M 10-K · filed 2019-02-26 | $78.32M derived: sum of 2 quarters · filed 2019-02-26 | $105.92M 10-Q · filed 2018-11-02 | |
| 2017-06-30 | $35.56M 10-K · filed 2019-02-26 | $63.16M 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | $27.60M 10-K · filed 2019-02-26 | |||
| 2016-12-31 | $81.32M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |